Hikma Pharmaceuticals Plc (LON:HIK)‘s stock had its “add” rating reaffirmed by analysts at Numis Securities Ltd in a note issued to investors on Friday, Marketbeat Ratings reports. They presently have a GBX 1,560 ($20.32) target price on the stock. Numis Securities Ltd’s target price would indicate a potential upside of 21.31% from the company’s previous close.

Several other research firms have also issued reports on HIK. HSBC Holdings plc reaffirmed a “reduce” rating and issued a GBX 1,800 ($23.44) price objective on shares of Hikma Pharmaceuticals Plc in a research note on Friday, May 5th. J P Morgan Chase & Co reduced their price objective on shares of Hikma Pharmaceuticals Plc from GBX 2,400 ($31.25) to GBX 1,800 ($23.44) and set a “neutral” rating for the company in a research note on Friday, May 12th. Jefferies Group LLC lowered shares of Hikma Pharmaceuticals Plc to an “underperform” rating and reduced their price objective for the company from GBX 2,162 ($28.15) to GBX 1,450 ($18.88) in a research note on Wednesday, May 17th. Citigroup Inc. reaffirmed a “neutral” rating and issued a GBX 1,550 ($20.18) price objective on shares of Hikma Pharmaceuticals Plc in a research note on Wednesday, June 28th. Finally, Barclays PLC reaffirmed an “overweight” rating and issued a GBX 2,200 ($28.65) price objective on shares of Hikma Pharmaceuticals Plc in a research note on Monday, July 3rd. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. Hikma Pharmaceuticals Plc has a consensus rating of “Hold” and an average target price of GBX 1,892.10 ($24.64).

Hikma Pharmaceuticals Plc (HIK) traded down 1.15% during mid-day trading on Friday, hitting GBX 1286.00. The stock had a trading volume of 514,609 shares. The firm’s market cap is GBX 3.10 billion. The company has a 50-day moving average of GBX 1,412.94 and a 200-day moving average of GBX 1,776.73. Hikma Pharmaceuticals Plc has a 12-month low of GBX 1,277.00 and a 12-month high of GBX 2,354.00.

WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/13/hikma-pharmaceuticals-plcs-lonhik-add-rating-reaffirmed-at-numis-securities-ltd.html.

Hikma Pharmaceuticals Plc Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals Plc (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.